AVXL vs BIIB: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AVXL and BIIB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AVXL and BIIB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company focused on the central nervous system. Its lead candidate, blarcamesine (also called ANAVEX 2-73), is an orally available small molecule that activates the sigma-1 receptor (encoded by the SIGMAR1 gene), a target involved in cellular stress responses and the health and survival of nerve cells. The company's thesis is that restoring cellular homeostasis through this pathway can slow neurodegeneration. Blarcamesine has completed a Phase 2b/3 trial (AD-004) in early Alzheimer's disease and has been studied in Parkinson's disease dementia and in Rett syndrome. A second candidate, ANAVEX 3-71, targets both SIGMAR1 and the M1 muscarinic receptor and is being advanced toward pivotal studies in schizophrenia-related disorders.

Full AVXL guide

Biogen is a Cambridge, Massachusetts biotechnology company built on neuroscience. Its historic core is multiple sclerosis (Tysabri, Tecfidera, Vumerity), and it co-developed the spinal muscular atrophy drug Spinraza with Ionis. Its growth story now centers on Leqembi, the Alzheimer's antibody it markets with partner Eisai, alongside newer rare-disease products Skyclarys (Friedreich's ataxia) and Qalsody (ALS). In 2026 it closed the roughly $5.6 billion acquisition of Apellis Pharmaceuticals, adding the retinal drug Syfovre for geographic atrophy and Empaveli for rare blood and kidney diseases.

Full BIIB guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AVXL drivers: Blarcamesine and the US regulatory path; Oral, small-molecule differentiation.
• BIIB drivers: Leqembi Alzheimer's ramp; Rare-disease and new-product portfolio.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The overriding risk is binary clinical and regulatory outcome: Anavex has no product revenue, so its value depends almost entirely on blarcamesine's fate. For BIIB, the legacy MS business (Tecfidera, Tysabri) continues to decline against generics and biosimilars, and full-year 2026 total revenue is guided down a mid-single-digit percentage.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AVXL if you believe its drivers more; BIIB if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AVXL and BIIB guides.

AVXL. Anavex is pre-revenue, so traditional valuation metrics like P/E do not apply; the market values it on the probability-weighted potential of its pipeline, chiefly blarcamesine. The figures above are approximate, tied to the asOf date, and drawn from company disclosures that can change quickly. Verify the latest cash position, regulatory status, and any financing before acting; for clinical-stage biotech, headlines can move the stock far more than any accounting number.

BIIB. Biogen trades at a low double-digit forward earnings multiple, well below the drug-manufacturer industry median, reflecting a shrinking legacy base and turnaround uncertainty. Q1 2026 earnings beat expectations on cost discipline and Leqembi momentum, but management still guides full-year revenue down a mid-single-digit percentage. The valuation prices in doubt that new launches will outrun legacy erosion.

Headline figures (approximate, Jul 2026): AVXL shows business stage Clinical-stage biopharmaceutical; pre-revenue (no approved products), lead asset Blarcamesine (ANAVEX 2-73), oral sigma-1 receptor activator for early Alzheimer's disease, revenue No meaningful product revenue; company is not yet commercial, cash position About $132 million as of Dec 31, 2025, with a stated runway of more than three years; BIIB shows revenue (ttm) ~$9.7B, q1 2026 revenue ~$2.5B (up ~2% YoY), q1 2026 non-gaap eps ~$3.57, market cap ~$29B.

AVXL and BIIB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AVXL and BIIB exposure against your real portfolio. It is not an investment adviser.